Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 7, 2025

PE anti-human CD366 (Tim-3)

RRID:AB_2116576
Type: Antibody

Proper Citation

(BioLegend Cat# 345006, RRID:AB_2116576)

Antibody Information

URL: http://antibodyregistry.org/AB_2116576

Proper Citation: (BioLegend Cat# 345006, RRID:AB_2116576)

Target Antigen: CD366

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-human CD366 (Tim-3)

Description: This monoclonal targets CD366

Target Organism: human

Clone ID: Clone F38-2E2

Antibody ID: AB_2116576

Vendor: BioLegend

Catalog Number: 345006

Alternative Catalog Numbers: 345005

Record Creation Time: 20231110T050415+0000

Record Last Update: 20241115T001734+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human CD366 (Tim-3).

No alerts have been found for PE anti-human CD366 (Tim-3).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Si X, et al. (2024) Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation. Cell metabolism, 36(1), 176.

Wang Z, et al. (2024) Suppression of the METTL3-m6A-integrin ?1 axis by extracellular acidification impairs T cell infiltration and antitumor activity. Cell reports, 43(2), 113796.

Liu Y, et al. (2024) IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects. iScience, 27(1), 108597.

Huang Y, et al. (2024) Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. Cell reports. Medicine, 5(2), 101400.

Wu L, et al. (2023) CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance. Cell reports. Medicine, 4(2), 100917.

Tamura T, et al. (2023) Single-cell transcriptomics reveal a hyperacute cytokine and immune checkpoint axis after cardiac arrest in patients with poor neurological outcome. Med (New York, N.Y.), 4(7), 432.

Ma X, et al. (2023) Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-? axis. Cell reports, 42(8), 112944.

Jung IY, et al. (2023) Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors. Cell reports. Medicine, 4(6), 101053.

Ducoin K, et al. (2022) Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy. Cancers, 14(17).

Ceppi F, et al. (2022) Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects. Cancer immunology research, 10(7), 856.

Ducoin K, et al. (2022) Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer. Oncoimmunology, 11(1), 2046931.

Srivastava S, et al. (2021) Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. Cancer cell, 39(2), 193.

Houtsma R, et al. (2021) CombiFlow: Flow cytometry-based identification and characterization of genetically and functionally distinct AML subclones. STAR protocols, 2(4), 100864.

de Boer B, et al. (2018) Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones. Cancer cell, 34(4), 674.